Biopharmaceutical firm Neumora Therapeutics, backed by Amgen and Japan’s SoftBank, is aiming to raise up to $264.8 million in its U.S. initial public offering, according to a regulatory filing on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
